Description of INGARON® (Nasal Drops)

INGARON® (100’000 IU) is a recombinant human interferon gamma, lyophilisate for intranasal solution (INGARON® nasal drops), it blocks the attachment and invasion of the virus to respiratory mucosa cells improving their resistance to infection.

INGARON® is an efficient antiviral and immunomodulatory drug.

Current achievements of domestic medicine allowed for the development of a new drug being both immunomodulatory and antiviral and showing high influenza and ARVI prevention and treatment efficiency. In comparison with other drugs, INGARON® possesses a strong antiviral activity. It blocks virus replication and kills infected cells. Moreover, INGARON® starts working immediately after it has been absorbed by the nasal mucosa that allows for maximum advancing its effect.

The antiviral drug for adults and children above 7 years of age under INGARON® trademark is manufactured by Research and Production Enterprise Pharmaclon, LLC, which conducts clinical studies under advanced research institutes for pharmacy and medicine: State Institution Research Institute of Influenza, the Russian Academy of Medical Sciences (St. Petersburg), State Educational Institution of Higher Professional Training of I. I. Mechnikov St. Petersburg State Medical Academy, the Russian Academy of Medical Sciences, State Institution The N. N. Blokhin Russian Oncological Research Center, Federal State Institution State Research Center for Dermatovenerology RosMedTechnologies, State Institution N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Federal State Institution The Russian Radiology Research Center, etc.

The development of national interferon gamma-based drug was started by the USSR scientists as early as in 1989, but due to the national reconstruction, the research has been completed relatively recently.

In 2002, Research and Production Enterprise Pharmaclon, Limited Liability Company developed and for the first time ever conducted a pilot production of original drug named INGARON® based on recombinant human interferon gamma. Unlike leucocyte interferons (produced from donated human blood), the major advantage of recombinant interferons is a high safety in respect of the possibility of human viruses transmission upon using the said interferons. In the same year, the development of INGARON® drug was patented under No 2214832 and registered in the State Registry of Inventions of the Russian Federation for 20 years. In 2006, Research and Production Enterprise Pharmaclon, LLC obtained a license (No 99-04-00133 d/d 19.01.2006) for the manufacture and marketing of the first patented and registered national interferon gamma-based INGARON® drug being the only one in Russia so far and presented in two pharmaceutical forms – lyophilizate for solution for intramuscular and subcutaneous injections, and lyophilizate for intranasal solution (nasal drops).

Clinical studies of the drug have showed its high efficiency against various agents. It makes the drug applicable against a variety of diseases, namely it is safe to say that INGARON® possesses a comprehensively wide antiviral activity (over 200 viruses). Interferon gamma has demonstrated particular strong effect against viral infections: influenza and ARVI. Thus, the new antiviral INGARON® drug is currently one of the most efficient drugs against these diseases.

According to the data from clinical studies conducted in the Outpatient Department of State Institution Research Institute of Influenza of the Russian Academy of Medical Sciences, in which patients with confirmed diagnosis of influenza and ARVI took part, INGARON® showed high tolerability, safety and apparent efficiency – twice less risk of complications and reduction of influenza and ARVI manifestations:

  • Fever by 1.7 times;
  • Headache by 2 times;
  • Cough by 1.7 times;
  • Rhinitis by 1.6 times

The results in the group of patients taking a preventive course of intranasal INGARON®, demonstrated the reduction of risk of being down with influenza or ARVI by 2.1 times.

Over 90% of diseases caused by respiratory viral infections can be prevented by intranasal administration of interferon gamma.

A trial of a number of drugs at the Research Institute of Influenza of the Ministry of Healthcare of the Russian Federation demonstrated that INGARON® is notable for the highest antiviral activity against the H1N1 strain of swine flu virus.

INGARON is efficient both for the prevention of influenza and ARVI and at any stage of viral infection development; moreover, INGARON does not lead to drug resistance, and no side effects were marked during its administration.

Easy to use form makes this antiviral and immunomodulatory drug optimal under the modern pace of life.

Marketing Authorization